Catalyst Pharmaceuticals CPRX Institutional Ownership

Their combined ownership stood at 89.3% of outstanding shares in June 2026, up from 86.7% in March 2026.

• They increased total shares held in Catalyst Pharmaceuticals by 21.17% from the prior quarter, while the number of investors in CPRX increased 8.82% year over year.
• Of these 395 funds, 219 grew their exposure to Catalyst Pharmaceuticals, 118 cut back, and 58 maintained positions.
• In total, institutional investors held 109.13Mn shares in Catalyst Pharmaceuticals as of June 2026, up by 19.06Mn shares quarter on quarter, and up 8.42Mn shares year over year.
• As of June 30, 2026, the biggest holder of Catalyst Pharmaceuticals is BlackRock, Inc. at 19.16Mn shares, representing 15.67% of shares outstanding.
• Top purchasers of CPRX stock for the quarter ending June 2026 included GLAZER CAPITAL, LLC (3.6Mn), HBK INVESTMENTS L P (2.82Mn), Jpmorgan Chase & Co (2.7Mn), Jupiter Topco LLC (2.28Mn), Qube Research & Technologies Ltd (1.84Mn).
• The largest sellers of Catalyst Pharmaceuticals for the quarter ending June 2026 were ROYCE & ASSOCIATES LP (1.73Mn), Bank Of America Corp /De/ (1.73Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (811.24K), VICTORY CAPITAL MANAGEMENT INC (734.55K), PRICE T ROWE ASSOCIATES INC /MD/ (614.83K).
• Per Business Quant, the top 10 investors in CPRX for the quarter ending June 2026 include BlackRock, Inc. (19.16Mn), State Street Corp (7.63Mn), AMERICAN CENTURY COMPANIES INC (5.55Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.14Mn), DIMENSIONAL FUND ADVISORS LP (3.63Mn), GLAZER CAPITAL, LLC (3.6Mn), Jpmorgan Chase & Co (3.17Mn), GEODE CAPITAL MANAGEMENT, LLC (3.15Mn), HBK INVESTMENTS L P (2.82Mn), Morgan Stanley (2.76Mn).